testimonial-03 By ef Posted 02/03/2017 In testimonial-032017-02-032017-02-03http://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.pngNouscomhttp://www.nouscom.com/wp-content/uploads/2017/01/client-03.png200px200px Recent PostsNouscom announces appointment of Yen Ching as Vice President of Clinical OperationsNouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal CancerDr. Marina Udier comments the Neoantigen vaccine report card issued by BioCenturyNouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
